Needham Lifts PT on Ionis Prescribed drugs (IONS) to $103 From $90

Ionis Prescribed drugs, Inc. (NASDAQ:IONS) is one in all one of the best robust purchase healthcare shares to spend money on. Ionis Prescribed drugs, Inc. (NASDAQ:IONS) launched its fiscal This fall and full-year 2025 earnings on February 25, reporting that complete income for the 12 months ended December 31, 2025, was $944 million in comparison with $705 within the earlier 12 months, significantly surpassing expectations because of continued industrial success. The corporate additionally earned substantial R&D income, together with a $280 million upfront fee for the worldwide license of sapablursen to Ono Pharmaceutical Co., Ltd. in fiscal Q2 2025. Whole income for This fall was $203 million, in comparison with $227 million within the prior 12 months interval.

Ionis Prescribed drugs, Inc. (NASDAQ:IONS) additional reported that working bills for the complete 12 months have been consistent with expectations and rose 12 months over 12 months from investments associated to commercialization efforts for TRYNGOLZA, DAWNZERA, and WAINUA. Following the ranking replace, Needham lifted the value goal on Ionis Prescribed drugs, Inc. (NASDAQ:IONS) to $103 from $90 on February 25, sustaining a Purchase ranking on the shares and telling buyers that it sees upside to the corporate’s 2026 income outlook because the 12 months progresses.

Ionis Prescribed drugs, Inc. (NASDAQ:IONS) develops and commercializes human therapeutic medication utilizing antisense know-how. It capabilities via the Ionis Core phase, which generates a pipeline of medication via a novel drug discovery platform.

Whereas we acknowledge the potential of IONS as an funding, we consider sure AI shares supply larger upside potential and carry much less draw back threat. For those who’re searching for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.

READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.

Disclosure: None. This text is initially revealed at Insider Monkey.